Moore Capital Management LP purchased a new stake in Geron Corporation (NASDAQ:GERN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,191,941 shares of the biopharmaceutical company's stock, valued at approximately $1,526,000. Moore Capital Management LP owned 0.19% of Geron at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of GERN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Geron by 2.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company's stock valued at $627,000 after purchasing an additional 8,123 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Geron by 8.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,372,016 shares of the biopharmaceutical company's stock valued at $2,182,000 after buying an additional 104,840 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Geron by 8.3% during the 2nd quarter. Legal & General Group Plc now owns 550,871 shares of the biopharmaceutical company's stock valued at $775,000 after acquiring an additional 42,345 shares during the period. Rhumbline Advisers increased its stake in Geron by 4.1% in the second quarter. Rhumbline Advisers now owns 873,893 shares of the biopharmaceutical company's stock valued at $1,232,000 after purchasing an additional 34,437 shares during the last quarter. Finally, Prudential Financial Inc. lifted its position in Geron by 72.3% during the second quarter. Prudential Financial Inc. now owns 79,494 shares of the biopharmaceutical company's stock worth $112,000 after buying an additional 33,352 shares during the period. Institutional investors and hedge funds own 73.71% of the company's stock.
Geron Stock Performance
Shares of NASDAQ:GERN opened at $1.49 on Tuesday. The business's 50-day simple moving average is $1.45 and its 200 day simple moving average is $1.48. The company has a market cap of $957.28 million, a P/E ratio of -13.55 and a beta of 0.61. The company has a debt-to-equity ratio of 0.55, a quick ratio of 5.16 and a current ratio of 6.91. Geron Corporation has a one year low of $1.04 and a one year high of $2.01.
Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The firm had revenue of $57.48 million during the quarter, compared to analyst estimates of $55.30 million. Geron had a negative net margin of 34.17% and a negative return on equity of 24.48%. On average, sell-side analysts forecast that Geron Corporation will post -0.04 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded Geron from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Geron presently has a consensus rating of "Hold" and a consensus price target of $4.00.
View Our Latest Stock Analysis on GERN
Geron Company Profile
(
Free Report)
Geron Corporation NASDAQ: GERN is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company's research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.
The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.
Recommended Stories
Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Corporation (NASDAQ:GERN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
